Takatsuki, Japan

Takeshi Noguchi


Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 79(Granted Patents)


Company Filing History:


Years Active: 1982-1983

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Inventor Takeshi Noguchi

Introduction

Takeshi Noguchi, an accomplished inventor based in Takatsuki, Japan, has made significant strides in the field of ophthalmology. With two patents to his name, he has developed methods and compositions aimed at treating glaucoma and ocular hypertension, showcasing his commitment to enhancing patient care.

Latest Patents

Takeshi Noguchi's latest patents include innovative approaches to treat glaucoma or ocular hypertension. One of his notable patents, titled "Method for the treatment of glaucoma or ocular hypertension by topically applying to the eye an effective amount of 2-(3-tert.-butylamino-2-hydroxypropylthio)-4-(5-carbamoyl-2-thienyl)-thiazole," focuses on lowering intraocular pressure efficiently. Additionally, he holds a patent for a pharmaceutical composition comprising bencyclane fumarate, which, when combined with cyclodextrin, reduces the adverse effects associated with previous formulations. This advancement also brings significant benefits in terms of use and production methods.

Career Highlights

Takeshi Noguchi is affiliated with Sumitomo Chemical Company, Limited, where he utilizes his expertise and knowledge to contribute to the development of innovative pharmaceutical solutions. His work emphasizes the importance of finding effective treatments for common yet serious eye conditions.

Collaborations

During his career, Noguchi has collaborated with notable coworkers including Yoshiya Yamahira and Kaoru Yamamori. These collaborations have fostered a rich environment for creativity and innovation within the realm of pharmaceutical development, resulting in groundbreaking advancements in ocular treatments.

Conclusion

Takeshi Noguchi's contributions to the field of ophthalmology through his patents signify his dedication to innovative healthcare solutions. As he continues to work with Sumitomo Chemical Company, Limited, the future holds great promise for further advancements in the treatment of glaucoma and ocular hypertension. His significant work not only underscores the importance of innovation in medicine but also highlights the ongoing need for research and development in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…